What is the first‑line antibiotic for acute sinusitis in a child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

First-Line Antibiotic for Pediatric Acute Bacterial Sinusitis

For most children ≥2 years old with uncomplicated, mild-to-moderate acute bacterial sinusitis, amoxicillin at 45 mg/kg/day divided twice daily is the first-line antibiotic. 1

Risk-Stratified Antibiotic Selection

The choice between amoxicillin alone versus amoxicillin-clavulanate depends on specific risk factors:

Standard-Dose Amoxicillin (45 mg/kg/day in 2 divided doses)

Use for children who meet ALL of the following criteria 1:

  • Age ≥2 years
  • Mild to moderate severity
  • No daycare attendance
  • No antibiotics in past 4 weeks
  • Community prevalence of nonsusceptible S. pneumoniae <10%

High-Dose Amoxicillin (80-90 mg/kg/day in 2 divided doses, max 2g/dose)

Use when 1:

  • Community prevalence of nonsusceptible S. pneumoniae >10%
  • Otherwise meets standard-dose criteria above

High-Dose Amoxicillin-Clavulanate (80-90 mg/kg/day of amoxicillin component with 6.4 mg/kg/day clavulanate in 2 divided doses)

Required for children with ANY of these risk factors 1:

  • Age <2 years
  • Moderate to severe illness at presentation
  • Daycare attendance
  • Recent antibiotic use (within past 30 days)

Important caveat: The 2012 IDSA guideline recommends amoxicillin-clavulanate over amoxicillin alone as first-line for all children with acute bacterial sinusitis 2. However, the 2013 AAP guideline provides more nuanced, risk-stratified recommendations that allow amoxicillin alone for low-risk children, which is more practical and reduces unnecessary clavulanate exposure 1.

Rationale for Amoxicillin

Amoxicillin remains first-line based on 1:

  • Proven effectiveness against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
  • Excellent safety profile
  • Acceptable taste for children
  • Low cost
  • Narrow microbiologic spectrum (reduces collateral damage to normal flora)

Alternative for Special Circumstances

Ceftriaxone 50 mg/kg IM/IV (single dose) 1:

  • For children who are vomiting
  • Unable to tolerate oral medication
  • Unlikely to be adherent initially
  • Provides 95-100% coverage of the three major pathogens
  • Switch to oral antibiotics after 24 hours if improved

Treatment Duration

10-14 days is recommended for children 2, or continue for 7 days after symptom resolution (minimum 10 days total) 1.

Common Pitfalls to Avoid

  • Don't prescribe antibiotics for viral rhinosinusitis: Only treat when strict clinical criteria are met (persistent symptoms >10 days without improvement, severe symptoms with high fever ≥102°F and purulent discharge for ≥3 consecutive days, or worsening symptoms after initial improvement) 1
  • Don't underdose: High-dose therapy is critical for overcoming resistance in at-risk populations
  • Don't use amoxicillin alone in high-risk children: β-lactamase-producing H. influenzae (10-42% prevalence) and M. catarrhalis (nearly 100%) will not respond 1
  • Don't routinely cover for MRSA: Not indicated for initial empiric therapy despite being a potential pathogen 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.